FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1854599992> ?p ?o ?g. }

• W1854599992 endingPage "661" @default.
• W1854599992 startingPage "654" @default.
• W1854599992 abstract "Aim Darapladib is a potent and reversible orally active inhibitor of lipoprotein‐associated phospholipase A 2 (Lp‐PLA 2 ). The aim of the study was to assess the effects of severe renal impairment on the pharmacokinetics and safety/tolerability of darapladib compared with normal renal function. Methods This was an open label, parallel group study of darapladib following 10 day once daily 160 mg oral dosing in subjects with normal ( n = 8) and severe renal impairment (estimated glomerular filtration rate <30 ml min –1 1.73 m –2 , n = 8). Plasma concentrations of total and unbound darapladib as well as total darapladib metabolites were determined in samples obtained over 24 h on day 10. Results Plasma concentrations of total and unbound darapladib as well as all three metabolites were higher in subjects with severe renal impairment. Area under the plasma concentration vs . time curve between time zero and 24 h (AUC(0,24 h) and maximum plasma concentration ( C max ) of total darapladib in severely renally impaired subjects were 52% and 59% higher than those in the matched healthy subjects, respectively. Similar results were found with the darapladib metabolites. Darapladib was highly plasma protein bound with 0.047% and 0.034% unbound circulating in plasma in severely renally impaired and healthy subjects, respectively. Unbound plasma darapladib exposures were more than two‐fold higher in severely renally impaired subjects than in healthy controls. Adverse events (AE) were reported in 38% of healthy subjects and 75% of severely renally impaired subjects, most of which were mild or moderate in intensity. Conclusions The results of this study showed that darapladib exposure was increased in subjects with severe renal impairment compared with healthy controls. However, darapladib was generally well tolerated in both groups." @default.
• W1854599992 created "2016-06-24" @default.
• W1854599992 creator A5008417673 @default.
• W1854599992 creator A5042540620 @default.
• W1854599992 creator A5074375293 @default.
• W1854599992 creator A5075463492 @default.
• W1854599992 creator A5090967553 @default.
• W1854599992 date "2015-07-06" @default.
• W1854599992 modified "2023-10-05" @default.
• W1854599992 title "The pharmacokinetics and safety of darapladib in subjects with severe renal impairment" @default.
• W1854599992 cites W1550111394 @default.
• W1854599992 cites W1586079541 @default.
• W1854599992 cites W1769836737 @default.
• W1854599992 cites W1965924089 @default.
• W1854599992 cites W1966337012 @default.
• W1854599992 cites W1992708043 @default.
• W1854599992 cites W2002047267 @default.
• W1854599992 cites W2026977556 @default.
• W1854599992 cites W2039796430 @default.
• W1854599992 cites W2040136554 @default.
• W1854599992 cites W2077149526 @default.
• W1854599992 cites W2099917925 @default.
• W1854599992 cites W2166392651 @default.
• W1854599992 doi "https://doi.org/10.1111/bcp.12661" @default.
• W1854599992 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4594701" @default.
• W1854599992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25953363" @default.
• W1854599992 hasPublicationYear "2015" @default.
• W1854599992 type Work @default.
• W1854599992 sameAs 1854599992 @default.
• W1854599992 citedByCount "2" @default.
• W1854599992 countsByYear W18545999922021 @default.
• W1854599992 countsByYear W18545999922022 @default.
• W1854599992 crossrefType "journal-article" @default.
• W1854599992 hasAuthorship W1854599992A5008417673 @default.
• W1854599992 hasAuthorship W1854599992A5042540620 @default.
• W1854599992 hasAuthorship W1854599992A5074375293 @default.
• W1854599992 hasAuthorship W1854599992A5075463492 @default.
• W1854599992 hasAuthorship W1854599992A5090967553 @default.
• W1854599992 hasBestOaLocation W18545999921 @default.
• W1854599992 hasConcept C112705442 @default.
• W1854599992 hasConcept C126322002 @default.
• W1854599992 hasConcept C126894567 @default.
• W1854599992 hasConcept C159641895 @default.
• W1854599992 hasConcept C197934379 @default.
• W1854599992 hasConcept C2777288759 @default.
• W1854599992 hasConcept C2778375690 @default.
• W1854599992 hasConcept C71924100 @default.
• W1854599992 hasConcept C98274493 @default.
• W1854599992 hasConceptScore W1854599992C112705442 @default.
• W1854599992 hasConceptScore W1854599992C126322002 @default.
• W1854599992 hasConceptScore W1854599992C126894567 @default.
• W1854599992 hasConceptScore W1854599992C159641895 @default.
• W1854599992 hasConceptScore W1854599992C197934379 @default.
• W1854599992 hasConceptScore W1854599992C2777288759 @default.
• W1854599992 hasConceptScore W1854599992C2778375690 @default.
• W1854599992 hasConceptScore W1854599992C71924100 @default.
• W1854599992 hasConceptScore W1854599992C98274493 @default.
• W1854599992 hasFunder F4320307773 @default.
• W1854599992 hasIssue "4" @default.
• W1854599992 hasLocation W18545999921 @default.
• W1854599992 hasLocation W18545999922 @default.
• W1854599992 hasLocation W18545999923 @default.
• W1854599992 hasLocation W18545999924 @default.
• W1854599992 hasOpenAccess W1854599992 @default.
• W1854599992 hasPrimaryLocation W18545999921 @default.
• W1854599992 hasRelatedWork W2037651778 @default.
• W1854599992 hasRelatedWork W2064759457 @default.
• W1854599992 hasRelatedWork W2074207917 @default.
• W1854599992 hasRelatedWork W2802776155 @default.
• W1854599992 hasRelatedWork W3087516196 @default.
• W1854599992 hasRelatedWork W3131642206 @default.
• W1854599992 hasRelatedWork W3160956384 @default.
• W1854599992 hasRelatedWork W4205587618 @default.
• W1854599992 hasRelatedWork W4296087748 @default.
• W1854599992 hasRelatedWork W4366822339 @default.
• W1854599992 hasVolume "80" @default.
• W1854599992 isParatext "false" @default.
• W1854599992 isRetracted "false" @default.
• W1854599992 magId "1854599992" @default.
• W1854599992 workType "article" @default.